Horizon Pharma Public Limited Company (HZNP)
(Delayed Data from NSDQ)
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up?
by Zacks Equity Research
During Assertio Therapeutics' (ASRT) Q1 conference call, investor focus will be on the company's progress with its neurology franchise and the NDA filing for cosyntropin.
Cronos (CRON) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when the company reports Q1 results.
What's in the Cards for Corbus (CRBP) This Earnings Season?
by Zacks Equity Research
Corbus (CRBP) will provide updates on its lead candidate lenabasum, when it releases first-quarter 2019 results.
Mylan (MYL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on the performance of Wixela Inhub, the newly launched biosimilars and other updates from Mylan (MYL)'s pipeline when the company shortly reports Q1 results.
What's in Store for Sorrento (SRNE) This Earnings Season?
by Zacks Equity Research
Sorrento (SRNE) may provide update on progress of ZTlido on the first quarter earnings call.
Regeneron (REGN) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports first-quarter results.
PDL BioPharma (PDLI) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During PDL BioPharma's (PDLI) Q1 conference call, investor focus will be on the company's ability to acquire new income-generating assets for frequent revenue growth.
What's in Store for BioDelivery (BDSI) This Earnings Season?
by Zacks Equity Research
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
What's in the Cards for AEterna (AEZS) This Earnings Season?
by Zacks Equity Research
AEterna (AEZS) may provide update on the path forward for Macrilen in Europe on the first-quarter earnings call.
Is a Beat in the Cards for Mallinckrodt (MNK) Q1 Earnings?
by Zacks Equity Research
Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q1 results on May 7.
Horizon Pharma (HZNP) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Horizon Pharma (HZNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is likely to provide update on the path forward for its two lead vaccine candidates.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, Zygel.
What's in the Cards for Sarepta (SRPT) This Earnings Season?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive first-quarter sales.
Why the Earnings Surprise Streak Could Continue for Horizon Pharma (HZNP)
by Zacks Equity Research
Horizon Pharma (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Is Horizon Pharma (HZNP) Down 9.9% Since Last Earnings Report?
by Zacks Equity Research
Horizon Pharma (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News For Mar 1, 2019
by Zacks Equity Research
Companies In The News Are: BKNG, HPQ, LB, HZNP
Why These Pharma ETFs Rallied on Thursday
by Sanghamitra Saha
A few pharma ETFs hit a one-month high on Feb 28. Why?
Horizon Pharma's (HZNP) Stock Up on Q4 Earnings & Sales Beat
by Zacks Equity Research
Horizon Pharma's (HZNP) earnings and sales beat estimates in the fourth quarter of 2018.
Horizon Pharma (HZNP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Horizon Pharma (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Horizon Pharma (HZNP) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Horizon Pharma (HZNP) stock based on the movements in the options market lately.
Horizon Pharma (HZNP) Up 28% on Business Expansion Strategy
by Zacks Equity Research
Horizon Pharma's (HZNP) share price increases about 28% based on its business expansion plan and acquisitions.
Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group
by Zacks Equity Research
Horizon Pharma's Ravicti Oral Liquid gets FDA approval to expand the age range to include infants younger than two months, living with a urea cycle disorder.
Horizon Pharma (HZNP) Down 9.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Horizon Pharma (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Horizon Pharma (HZNP) Q3 Earnings & Sales Beat, Shares Rise
by Zacks Equity Research
Shares of Horizon Pharma (HZNP) rise almost 16%, owing to record quarterly sales during the third quarter of 2018.